Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy?

Strong rationale and a growing number of preclinical and clinical studies support combining radiotherapy and immunotherapy to improve patient outcomes. However, several critical questions remain, such as the identification of patients who will benefit from immunotherapy and the identification of the best modalities of treatment to optimize patient response. Imaging biomarkers and radiomics have recently emerged as promising tools for the non-invasive assessment of the whole disease of the patient, allowing comprehensive analysis of the tumor microenvironment, the spatial heterogeneity of the disease and its temporal changes. This review presents the potential applications of medical imaging and the challenges to address, in order to help clinicians choose the optimal modalities of both radiotherapy and immunotherapy, to predict patient’s outcomes and to assess response to these promising combinations.

[1]  Jianjiong Gao,et al.  Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer , 2022, Nature Cancer.

[2]  Jun Cheng,et al.  Differentiation between immune checkpoint inhibitor‐related and radiation pneumonitis in lung cancer by CT radiomics and machine learning , 2022, Medical physics.

[3]  N. Lennon,et al.  Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. , 2022, The Lancet. Oncology.

[4]  A. Fedeli,et al.  Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics , 2022, Cancers.

[5]  I. C. Kok,et al.  89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Adria Font Calvarons,et al.  A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma , 2021, Journal for ImmunoTherapy of Cancer.

[7]  Zhiguo Zhou,et al.  Immunotherapy treatment outcome prediction in metastatic melanoma through an automated multi-objective delta-radiomics model , 2021, Comput. Biol. Medicine.

[8]  John O. Prior,et al.  Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy , 2021, Cancer discovery.

[9]  S. Welford,et al.  Toward prediction of abscopal effect in radioimmunotherapy: Pre-clinical investigation , 2021, PloS one.

[10]  A. Feng,et al.  Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features , 2021, Frontiers in Oncology.

[11]  Xiu-juan Lei,et al.  Association predictions of genomics, proteinomics, transcriptomics, microbiome, metabolomics, pathomics, radiomics, drug, symptoms, environment factor, and disease networks: A comprehensive approach , 2021, Medicinal research reviews.

[12]  F. Mazzoni,et al.  Preliminary Report on Computed Tomography Radiomics Features as Biomarkers to Immunotherapy Selection in Lung Adenocarcinoma Patients , 2021, Cancers.

[13]  Mengchao Zhang,et al.  Radiomics Analysis of Multi-Sequence MR Images For Predicting Microsatellite Instability Status Preoperatively in Rectal Cancer , 2021, Frontiers in Oncology.

[14]  Yusheng Ye,et al.  Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial. , 2021, The Lancet. Oncology.

[15]  C. Zhou,et al.  Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer , 2021, Respiratory Research.

[16]  Ruijiang Li,et al.  Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study. , 2021, The Lancet. Digital health.

[17]  L. Mainardi,et al.  A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study , 2021, Diagnostics.

[18]  R. Gillies,et al.  Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer , 2021, JNCI cancer spectrum.

[19]  X. Ye,et al.  Pre-Immunotherapy Contrast-Enhanced CT Texture-Based Classification: A Useful Approach to Non-Small Cell Lung Cancer Immunotherapy Efficacy Prediction , 2021, Frontiers in Oncology.

[20]  A. Murphy,et al.  Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses , 2021, Science Immunology.

[21]  J. Pearson,et al.  Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients , 2021, Molecular Cancer Research.

[22]  K. Harrington,et al.  Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. , 2021, The Lancet. Oncology.

[23]  S. Bakas,et al.  Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers , 2021, Journal for ImmunoTherapy of Cancer.

[24]  M. Filetti,et al.  CT based radiomic approach on first line pembrolizumab in lung cancer , 2021, Scientific Reports.

[25]  A. Addeo,et al.  Three-Dimensional Deep Noninvasive Radiomics for the Prediction of Disease Control in Patients With Metastatic Urothelial Carcinoma treated With Immunotherapy. , 2021, Clinical genitourinary cancer.

[26]  Z. Ye,et al.  Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer , 2021, Frontiers in Oncology.

[27]  H. Aerts,et al.  Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving Immunotherapy , 2021, Frontiers in Oncology.

[28]  QUAN LIU,et al.  A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer , 2021, Frontiers in Oncology.

[29]  Bingbing Ni,et al.  A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer. , 2021, American journal of translational research.

[30]  R. Fietkau,et al.  Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors , 2021, Journal for ImmunoTherapy of Cancer.

[31]  N. Obuchowski,et al.  Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers , 2021, European Radiology.

[32]  C. Porta,et al.  A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC , 2020, Cancer Immunology, Immunotherapy.

[33]  A. Omuro,et al.  Comparison of Radiomic Feature Aggregation Methods for Patients with Multiple Tumors , 2020, medRxiv.

[34]  N. Paragios,et al.  Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells , 2020, Journal for ImmunoTherapy of Cancer.

[35]  Joe Y. Chang,et al.  Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. , 2020, The Lancet. Respiratory medicine.

[36]  Joe Y. Chang,et al.  Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial , 2020, Journal for ImmunoTherapy of Cancer.

[37]  A. Shinagare,et al.  Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors. , 2020, European urology oncology.

[38]  Jinming Yu,et al.  Application and Prospects of Molecular Imaging in Immunotherapy , 2020, Cancer management and research.

[39]  N. Lee,et al.  Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Joe Y. Chang,et al.  Use of Multi-Site Radiation Therapy as Systemic Therapy: A New Treatment Approach Personalized by Patient Immune Status. , 2020, International Journal of Radiation Oncology, Biology, Physics.

[41]  R. Jeraj,et al.  [18F]FDG PET Immunotherapy Radiomics Signature (iRADIOMICS) Predicts Response of Non-small-cell Lung Cancer Patients Treated with Pembrolizumab , 2020, Radiology and oncology.

[42]  Nikos Paragios,et al.  Standardization of brain MR images across machines and protocols: bridging the gap for MRI-based radiomics , 2020, Scientific Reports.

[43]  Nikos Paragios,et al.  Reinventing Radiation Therapy with Machine Learning and Imaging Bio-markers (Radiomics): state-of-the-art, challenges and perspectives. , 2020, Methods.

[44]  K. Bensalah,et al.  Radiomics can predict tumour response in patients treated with Nivolumab for a metastatic renal cell carcinoma: an artificial intelligence concept , 2020, World Journal of Urology.

[45]  D. Dong,et al.  Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker , 2020, Journal for ImmunoTherapy of Cancer.

[46]  K. Ghaghada,et al.  Detection of response to tumor microenvironment–targeted cellular immunotherapy using nano-radiomics , 2020, Science Advances.

[47]  M. Polley,et al.  A Validated T Cell Radiomics Score is Associated with Clinical Outcomes Following Multi-site SBRT and Pembrolizumab. , 2020, International journal of radiation oncology, biology, physics.

[48]  L. Schwartz,et al.  Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  C. Faivre-Finn,et al.  Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype , 2020, Lung cancer.

[50]  A. Benson,et al.  Detection of Immunotherapeutic Response in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI Radiomics: A Preliminary Investigation. , 2020, Academic radiology.

[51]  Hongbing Lu,et al.  Survival-relevant high-risk subregion identification for glioblastoma patients: the MRI-based multiple instance learning approach , 2020, European Radiology.

[52]  Jeong Kon Kim,et al.  Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma , 2020, European Radiology.

[53]  S. Novello,et al.  18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival , 2020, Cancers.

[54]  T. Nakano,et al.  Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment , 2020, International Journal of Clinical Oncology.

[55]  R. Steenbakkers,et al.  The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. , 2020, Radiology.

[56]  Jason M. Johnson,et al.  Phase I study of intraventricular infusions of autologous ex-vivo-expanded NK cells in children with recurrent medulloblastoma and ependymoma. , 2020, Neuro-oncology.

[57]  E. Deutsch,et al.  Radiotherapy–immunotherapy combinations – perspectives and challenges , 2020, Molecular oncology.

[58]  B. Taouli,et al.  MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma , 2020, European Radiology.

[59]  H. Lee,et al.  Utility of CT radiomics for prediction of PD‐L1 expression in advanced lung adenocarcinomas , 2020, Thoracic cancer.

[60]  Lisheng Wang,et al.  Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result. , 2020, Academic radiology.

[61]  J. Galon,et al.  Multiverse of immune microenvironment in metastatic colorectal cancer , 2020, Oncoimmunology.

[62]  Kathryn J Fowler,et al.  Assessing Radiology Research on Artificial Intelligence: A Brief Guide for Authors, Reviewers, and Readers-From the Radiology Editorial Board. , 2019, Radiology.

[63]  C. H. Nielsen,et al.  Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[64]  R. Gillies,et al.  Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[65]  Aaron Carass,et al.  DeepHarmony: A deep learning approach to contrast harmonization across scanner changes. , 2019, Magnetic resonance imaging.

[66]  Sinae Kim,et al.  Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. , 2019, International journal of radiation oncology, biology, physics.

[67]  Xiaoli Tang,et al.  The role of artificial intelligence in medical imaging research , 2019, BJR open.

[68]  A. Madabhushi,et al.  Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non–Small Cell Lung Cancer , 2019, Cancer Immunology Research.

[69]  Amber L. Simpson,et al.  Radiomics-based prediction of microsatellite instability in colorectal cancer at initial computed tomography evaluation , 2019, Abdominal Radiology.

[70]  J. Aerts,et al.  Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.

[71]  G. Coukos,et al.  Rational combinations of immunotherapy with radiotherapy in ovarian cancer. , 2019, The Lancet. Oncology.

[72]  Eric Deutsch,et al.  Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. , 2019, The Lancet. Oncology.

[73]  E. Goetghebeur,et al.  Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. , 2019, European urology.

[74]  Emily B. Ehlerding,et al.  Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with 89Zr-Df-Atezolizumab. , 2019, Bioconjugate chemistry.

[75]  H. Aerts,et al.  Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  R. Gillies,et al.  Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report. , 2019, Lung cancer.

[77]  V. Servois,et al.  Novel patterns of response under immunotherapy , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[78]  Fanny Orlhac,et al.  Validation of A Method to Compensate Multicenter Effects Affecting CT Radiomics. , 2019, Radiology.

[79]  D. Gu,et al.  Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging , 2019, European Radiology.

[80]  Benjamin Haibe-Kains,et al.  Vulnerabilities of radiomic signature development: The need for safeguards. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[81]  A. Debucquoy,et al.  The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients. , 2018, Cancer cell.

[82]  Joe Y. Chang,et al.  Time to abandon single-site irradiation for inducing abscopal effects , 2018, Nature Reviews Clinical Oncology.

[83]  Irène Buvat,et al.  Radiomics in Nuclear Medicine Applied to Radiation Therapy: Methods, Pitfalls, and Challenges. , 2018, International journal of radiation oncology, biology, physics.

[84]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[85]  N. Paragios,et al.  A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. , 2018, The Lancet. Oncology.

[86]  Josien P. W. Pluim,et al.  Not‐so‐supervised: A survey of semi‐supervised, multi‐instance, and transfer learning in medical image analysis , 2018, Medical Image Anal..

[87]  Steven J. M. Jones,et al.  The Immune Landscape of Cancer , 2018, Immunity.

[88]  R. Fietkau,et al.  Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies , 2018, Strahlentherapie und Onkologie.

[89]  Manish R. Sharma,et al.  Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  J. Wolchok,et al.  Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  R. Fietkau,et al.  Immunomodulation by ionizing radiation—impact for design of radio‐immunotherapies and for treatment of inflammatory diseases , 2017, Immunological reviews.

[92]  Andriy Fedorov,et al.  Computational Radiomics System to Decode the Radiographic Phenotype. , 2017, Cancer research.

[93]  P. Lambin,et al.  Radiomics: the bridge between medical imaging and personalized medicine , 2017, Nature Reviews Clinical Oncology.

[94]  J. Melotek,et al.  The ADscopal Effect? Control of Partially Irradiated Versus Completely Irradiated Tumors on a Prospective Trial of Pembrolizumab and SBRT Per NRG-BR001 , 2017 .

[95]  Eric Deutsch,et al.  [Computational medical imaging (radiomics) and potential for immuno-oncology]. , 2017, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[96]  P. Lambin,et al.  Defining the biological basis of radiomic phenotypes in lung cancer , 2017, eLife.

[97]  C. N. Coleman,et al.  DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity , 2017, Nature Communications.

[98]  N. Paragios,et al.  Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[99]  R. Ferris,et al.  Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma , 2017, Oncoimmunology.

[100]  F. Mornex,et al.  [Immunotherapy and radiotherapy]. , 2017, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[101]  Ragini Verma,et al.  Harmonization of multi-site diffusion tensor imaging data , 2017, NeuroImage.

[102]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[103]  Ralph R. Weichselbaum,et al.  Radiotherapy and immunotherapy: a beneficial liaison? , 2017, Nature Reviews Clinical Oncology.

[104]  Guy Cazuguel,et al.  Multiple-Instance Learning for Medical Image and Video Analysis , 2017, IEEE Reviews in Biomedical Engineering.

[105]  Charles Ferté,et al.  Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 , 2016, Clinical Cancer Research.

[106]  J. Wolchok,et al.  Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  Eric Deutsch,et al.  In Regard to Mattonen et al. , 2016, International journal of radiation oncology, biology, physics.

[108]  T. Schmid,et al.  Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma , 2016, Cancer Immunology Research.

[109]  H. Aerts,et al.  Applications and limitations of radiomics , 2016, Physics in medicine and biology.

[110]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[111]  M. Bartholomä,et al.  High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers , 2016, Theranostics.

[112]  Miao-Fen Chen,et al.  The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression , 2016, Oncotarget.

[113]  I. Weissman,et al.  Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging , 2015, Proceedings of the National Academy of Sciences.

[114]  S. Gambhir,et al.  Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes. , 2015, Bioconjugate chemistry.

[115]  Marion Smits,et al.  Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. , 2015, Neuro-oncology.

[116]  S. Demaria,et al.  Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. , 2015, The Lancet. Oncology.

[117]  Joe Y. Chang,et al.  The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. , 2015, Cancer treatment reviews.

[118]  H. Kohrt,et al.  Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions , 2015, Clinical Cancer Research.

[119]  H. Ishwaran,et al.  Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.

[120]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[121]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[122]  S. Demaria,et al.  Combining radiotherapy and cancer immunotherapy: a paradigm shift. , 2013, Journal of the National Cancer Institute.

[123]  R. Johnstone,et al.  Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. , 2012, Cancer research.

[124]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[125]  R. Gillies,et al.  The biology underlying molecular imaging in oncology: from genome to anatome and back again. , 2010, Clinical radiology.

[126]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[127]  N. Kawashima,et al.  Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.

[128]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[129]  S. Demaria,et al.  Systemic effects of local radiotherapy. , 2009, The Lancet. Oncology.

[130]  N. Kawashima,et al.  Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. , 2004, International journal of radiation oncology, biology, physics.

[131]  Wendy Brown,et al.  Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[132]  Yoshua Bengio,et al.  Convolutional networks for images, speech, and time series , 1998 .

[133]  G. Kalemkerian,et al.  Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.

[134]  A. Ribas,et al.  An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. , 2016, Cancer research.

[135]  Heather Zeiger,et al.  An Update on Genetic Testing: Separating the Hope from the Hype , 2012 .

[136]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[137]  John Adams Assessing , 2020, Transport Planning.

[138]  R. Mole Whole body irradiation; radiobiology or medicine? , 1953, The British journal of radiology.